Description
Subtitle: New legislation in Germany provides another piece of a complex puzzle; Editorial discussing Germany's "Pharmaceuticals Market Reorganisation Act" (AMNOG) and its effect on pharmaceutical clinical trial transparencyCitation
Doshi, P. & Jefferson, T. (2015). The evidence base for new drugs. BMJ, 350. DOI: 10.1136/bmj.h952Keyword
Pharmaceuticals Market Reorganisation Actresearch transparency
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Systematic reviews (Medical research)
Drug Industry--legislation & jurisprudence
Identifier to cite or link to this item
http://hdl.handle.net/10713/6606ae974a485f413a2113503eed53cd6c53
10.1136/bmj.h952